Piperacillin-tazobactam versus imipenem-cilastatin for treatment of intra-abdominal infections.
about
Antibiotic regimens for secondary peritonitis of gastrointestinal origin in adultsCanadian practice guidelines for surgical intra-abdominal infectionsClinical review: balancing the therapeutic, safety, and economic issues underlying effective antipseudomonal carbapenem useResults of a clinical trial of clinafloxacin versus imipenem/cilastatin for intraabdominal infectionsCharacterization of a PSE-4 mutant with different properties in relation to penicillanic acid sulfones: importance of residues 216 to 218 in class A beta-lactamases.Monobactams and carbapenems for treatment of intraabdominal infections.Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis.Pharmacodynamics of piperacillin alone and in combination with tazobactam against piperacillin-resistant and -susceptible organisms in an in vitro model of infection.New advances in the use of antimicrobial agents in surgery: intra-abdominal infections.Monotherapy with a broad-spectrum beta-lactam is as effective as its combination with an aminoglycoside in treatment of severe generalized peritonitis: a multicenter randomized controlled trial. The Severe Generalized Peritonitis Study GroupPharmacokinetics and pharmacodynamics of two multiple-dose piperacillin-tazobactam regimens.Clinical role of beta-lactam/beta-lactamase inhibitor combinations.Cross-Canada survey of resistance of 2747 aerobic blood culture isolates to piperacillin/tazobactam and other antibiotics.Study of the comparative activity of piperacillin/tazobactam with currently available antibiotics against 8206 aerobic isolates.Tigecycline in the treatment of complicated intra-abdominal and complicated skin and skin structure infections.Experience with the use of piperacillin-tazobactam in pediatric non-renal solid organ transplantation.Piperacillin-tazobactam penetration into human pancreatic juice.Carbapenems versus other beta-lactams in treating severe infections in intensive care: a systematic review of randomised controlled trials.Piperacillin/tazobactam: a new beta-lactam/beta-lactamase inhibitor combination.Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections.Beta-lactam resistance in anaerobic bacteria: a review.A practical look at the clinical usefulness of the beta-lactam/beta-lactamase inhibitor combinations.Intra-abdominal anaerobic infections: bacteriology and therapeutic potential of newer antimicrobial carbapenem, fluoroquinolone, and desfluoroquinolone therapeutic agents.Co-administration of vancomycin and piperacillin-tazobactam is associated with increased renal dysfunction in adult and pediatric burn patients.An open, multicenter clinical trial of piperacillin/tazobactam in the treatment of pediatric patients with intra-abdominal infections.The microbiology of postoperative peritonitis.Biapenem versus imipenem/cilastatin in the treatment of complicated intra-abdominal infections: report from a Swedish Study Group.Emergence of piperacillin/tazobactam-resistant Escherichia coli.Review of piperacillin/tazobactam in the treatment of bacteremic infections and summary of clinical efficacy.Piperacillin/tazobactam in the treatment of polymicrobial infections.
P2860
Q24246927-BD611808-8F77-4C0F-909B-88BAB7EED2A0Q24599288-61ABD218-1DDA-40E2-A914-881A9665ED4DQ28299749-FDDAFFB6-1D0F-4BB3-A669-17BC36AAF30BQ28345630-E8534F2D-DBDA-495F-8951-53934EDAFE2DQ32022049-0148A410-D5F1-4FD4-AF99-1AD3C3B1AE9DQ33603331-7B636380-04C4-4CD8-83B4-2F077D14FB27Q33701687-0257D852-7B28-4860-9169-B3F22C34E730Q33761118-B9C0D41A-1FAF-43F1-AB3B-C37CC3FC1207Q33840063-F1EE3BFE-1017-4FDF-9C81-ACB9CED903B0Q33980144-EC81F1CD-099C-4EA2-8EF9-29E0E36E2C0DQ35139002-98C14973-BEB4-4DBC-BA91-1A6A1CA5EDCCQ35166387-826538D6-6457-48C6-96BF-B297309041A1Q35650111-0DAAB4FC-CF3B-4880-8DA5-FE20B71AED9AQ35891315-C30BBD85-B971-4B80-A24A-08A6D4920FAFQ36663656-602BA86E-4AEA-4258-A074-54415DF1AF26Q36713376-168DB5F2-481F-43BB-8595-00D0C16FEE90Q36949427-6D62FB89-A852-4082-93D2-67DED8AC9C75Q37121661-A8BC9884-68E6-4B0C-8AFA-CA0F744133F8Q40471195-B8C506A0-BCD2-40A4-809E-F57B702B71A2Q40558538-8F6EE14A-5DB2-4677-B598-BB71A9D18AF6Q41134735-6583B4F9-8BC6-41D5-B37E-9FF90D63059EQ41189315-4B0A45EC-9A31-4884-B2C1-69330ABD0356Q43767713-E22F0288-BDA6-4E3C-AC30-E2A441492F9AQ47106329-CDFE36EA-E32B-4183-9685-E0AF30B7D6C3Q53989640-1C6FBD28-9957-4D10-9AE6-ACEEC5AFD97EQ53993089-CFC11566-840D-4DC1-9BE8-E07E7238DD70Q53993909-F8055FDF-362A-41B3-84B5-73BA8B447306Q54026065-97B163F5-F192-4021-9196-A0A8844284ADQ54200563-43112BB6-4C3C-4B7E-B0B4-38CDC78E3F30Q54200566-5ED429BE-4BC6-4A5B-9C0B-4D10C4DB2607
P2860
Piperacillin-tazobactam versus imipenem-cilastatin for treatment of intra-abdominal infections.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
1992年论文
@zh
1992年论文
@zh-cn
name
Piperacillin-tazobactam versus ...... of intra-abdominal infections.
@ast
Piperacillin-tazobactam versus ...... of intra-abdominal infections.
@en
type
label
Piperacillin-tazobactam versus ...... of intra-abdominal infections.
@ast
Piperacillin-tazobactam versus ...... of intra-abdominal infections.
@en
prefLabel
Piperacillin-tazobactam versus ...... of intra-abdominal infections.
@ast
Piperacillin-tazobactam versus ...... of intra-abdominal infections.
@en
P2093
P2860
P356
P1476
Piperacillin-tazobactam versus ...... of intra-abdominal infections.
@en
P2093
Bäckstrand B
Kihlström E
Malmborg AS
Mentzing LO
Nyström PO
Tunevall G
Wretlind B
P2860
P304
P356
10.1128/AAC.36.12.2766
P407
P577
1992-12-01T00:00:00Z